Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in young children with TSC, Dravet syndrome, or LGS
NCT04485104Phase 3Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of cannabidiol in epilepsy, sponsored by Jazz Pharmaceuticals plc. Started May 2021; status: terminated.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04485104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485104.